
Sanofi has launched a new healthcare app called Monster Manor to help children with type 1 diabetes better manage their …

In a blow to its diabetes pipeline, Sanofi has withdrawn a new drug application (NDA) for lixisenatide in the US …

GSK has established a $50 million venture capital fund to invest in the emerging field of bioelectronics. Described as one …

The FDA is making GlaxoSmithKline wait for a verdict on the manufacturer’s investigational type 2 diabetes treatment albiglutide, extending its …
Boehringer Ingelheim has partnered with Healthrageous and United BioSource to establish a new diabetes study to help patients manage their …

Roche has stopped a late-stage trial of its investigational diabetes drug aleglitazar over safety concerns. The move was prompted by …

A groundbreaking new study suggests that the body’s immune system can be taught to reverse the effects of type 1 …

New clinical trial results have shown Lilly’s investigational type 2 diabetes drug has beaten its three nearest rivals in reducing …

AstraZeneca R&D subsidiary MedImmune has signed a deal with privately-owned San Francisco-based NGM Biopharmaceuticals to discover novel therapeutics to treat …

A new investigation by Channel 4’s Dispatches and the British Medical Journal is demanding that all trial data be released …

Pfizer and Merck have unveiled a major new alliance in diabetes which is likely to raise the stakes in the …

Eli Lilly and Co’s new type II diabetes candidate dulaglutide – which it intends to file this year – has …

Merck KGaA and Bristol-Myers Squibb are to co-promote the German firm’s veteran diabetes drug Glucophage in different formations in China. …

Novo Nordisk has reported underwhelming results for a well-established diabetes treatment in a late-stage trial designed to test its weight …

Janssen has submitted a combination of its investigational diabetes drug canagliflozin with immediate-release metformin to the European Medicines Agency.The manufacturer, …